Abstract 17157: The SGLT2 Inhibitor Empagliflozin Ameliorates Interstitial Myocardial Fibrosis and Aortic Stiffness in Non-Diabetic Patients With Heart Failure With Reduced Ejection Fraction: A Secondary Analysis of the EMPATROPISM Trial

Carlos G. Santos-Gallego,Juan Antonio Requena Ibanez,Ariana P Vargas,Alvaro Garcia-Ropero,Anderly Rodriguez-Cordero,D. Mancini,Sean Pinney,Anuradha Lala,Johanna Contreras,Pedro R. Moreno,Javier Sanz,Valentin Fuster,Juan J. Badimon

Abstract 17157: The SGLT2 Inhibitor Empagliflozin Ameliorates Interstitial Myocardial Fibrosis and Aortic Stiffness in Non-Diabetic Patients With Heart Failure With Reduced Ejection Fraction: A Secondary Analysis of the EMPATROPISM Trial

2020

Carlos G. Santos-Gallego
Juan Antonio Requena Ibanez
Ariana P Vargas
Alvaro Garcia-Ropero
Anderly Rodriguez-Cordero
D. Mancini
Sean Pinney
Anuradha Lala
Johanna Contreras
Pedro R. Moreno
Javier Sanz
Valentin Fuster
Juan J. Badimon

Background: SGLT2 inhibitors (SGLT2i) improve prognosis in HFrEF patients. We recently demonstrated in a porcine model of non-diabetic HFrEF that empagliflozin (EMPA) ameliorates adverse cardiac re...

Keywords:

non diabetic
Ejection fraction
Internal medicine
secondary analysis
Medicine
myocardial fibrosis
Cardiology
SGLT2 Inhibitor
aortic stiffness
Empagliflozin
Heart failure

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations